Anika Therapeutics Inc. Gross Margin

Gross Margin of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending June 29, 2021 was 54.56% (a -10.79% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin decreased by -0.29%
  • Annual Gross Margin for 2020 was 52.91% (a -29.38% decrease from previous year)
  • Annual Gross Margin for 2019 was 74.92% (a 6.47% increase from previous year)
  • Annual Gross Margin for 2018 was 70.37% (a -7.25% decrease from previous year)
  • Twelve month Gross Margin ending June 29, 2021 was 55.46% (a 4.27% increase compared to previous quarter)
  • Twelve month trailing Gross Margin decreased by -3.63% year-over-year
Trailing Gross Margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
55.46% 53.19% 52.91% 57.55%
Visit stockrow.com/ANIK for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of Anika Therapeutics Inc.

Most recent Gross Marginof ANIK including historical data for past 10 years.

Interactive Chart of Gross Margin of Anika Therapeutics Inc.

Anika Therapeutics Inc. Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 54.56% 61.16%
2020 51.23% 54.72% 44.79% 59.88% 52.91%
2019 70.95% 79.96% 77.53% 70.43% 74.92%
2018 74.03% 69.08% 73.31% 63.11% 70.37%
2017 70.34% 77.01% 81.13% 73.99% 75.87%
2016 73.76% 80.62% 77.18% 75.65% 76.76%
2015 79.64% 78.14% 76.97% 72.21% 77.36%
2014 76.3% 74.04% 79.7% 87.18% 80.18%
2013 70.66% 69.71% 69.7% 68.25% 69.68%
2012 67.84% 51.1% 58.81% 55.34% 59.38%
2011 61.35% 59.93% 58.76% 52.25% 58.65%
2010 54.47% 57.11%

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.